Press release
Biosimilar Monoclonal Antibodies Market Analysis by Product Type and Indication Forecast to 2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Biosimilar Monoclonal Antibodies Market- by Product (Infliximab, Trastuzumab, Rituximab, Adalimumab, Bevacizumab, Cetuximab, Ranibizumab, Denosumab, Eculizumab and Other Pipeline Products), Indication (Oncology, Inflammatory & Autoimmune Disorders, Chronic Diseases, Blood Disorders and Other Indication), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1218
According to the latest research by InsightAce Analytic, the global Biosimilar Monoclonal Antibodies market is valued at USD 7.8 Billion in 2024. It is expected to reach USD 32.1 Billion by the year 2034, with a CAGR of 15.3% during a forecast period of 2025-2034.
The production of monoclonal antibodies (mAbs) involves the utilization of identical immune cell clones derived from a single parent cell. Monoclonal antibodies generated from the same parent cell are termed biosimilar monoclonal antibodies, as they closely resemble the original reference biologic in terms of quality, efficacy, and safety. These biosimilars constitute an important class of biotherapeutic products. Due to their complex biological nature, mAb biosimilars undergo extensive post-translational modifications. They are widely employed in the treatment of various autoimmune, inflammatory, and chronic diseases.
The global biosimilar monoclonal antibody market is driven by factors such as the increasing production of advanced mAbs, the growing elderly population, and the high prevalence of chronic conditions including cancer, kidney failure, rheumatoid arthritis, psoriasis, and diabetes. The expiration of patents on several key monoclonal antibodies is expected to create significant market opportunities in the coming years. Demand for mAbs is projected to accelerate throughout the forecast period, fueled by these patent expirations.
Nevertheless, the market faces challenges including the inherent complexity of biologic drug manufacturing, limited clinical trial experience, stringent regulatory requirements for product approvals, and a lack of comprehensive awareness among manufacturers regarding biosimilar regulatory pathways. These factors may constrain market growth to some extent.
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02
North America is anticipated to be the major contributor to the Biosimilar Monoclonal Antibodies market over the forecast years. The region's strong growth can be ascribed to increased product approvals, a well-established health care infrastructure, and a favorable reimbursement scenario. In addition, the Asia Pacific regional market is expected to register significant growth during the estimated period because chronic disease burden, the need for affordable therapies, and government funding for healthcare facility improvements are all on the rise.
Major market players operating in the Biosimilar Monoclonal Antibodies market include
BioXpress Therapeutics (Switzerland), Intas Pharmaceuticals Limited (Gujarat), Genor BioPharma Co. Ltd (China), BIOCAD (Russia), Dr. Reddys Laboratories Ltd (Hyderabad), 3SBio (China), Reliance Life Sciences (India), Hisun Pharma (China), Celgen Biopharma (China), Torrent Pharmaceuticals (Ahmedabad), Cadila Healthcare (Cadila Healthcare), Mylan Inc. (US) and others.
Recent collaborations and agreements in the market:
• In July 2021, Abzena (UK), a global partner research organization for biologics and bioconjugates, and BioXpress Therapeutics (Switzerland) collaborated to support third-party biosimilar development. This collaboration resulted in an integrated solution by two prominent service providers in biosimilar development and GMP manufacturing.
• In February 2021, Mylan (US) introduced Ogivri, a trastuzumab biosimilar. Trastuzumab is a monoclonal antibody used to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer, previously sold as Herceptin by Genentech.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1218
Market Segments
Global Biosimilar Monoclonal Antibodies Market, by Product, 2022-2030 (Value US$ Mn)
• Infliximab
• Trastuzumab
• Rituximab
• Adalimumab
• Bevacizumab
• Cetuximab
• Ranibizumab
• Denosumab
• Eculizumab
• Other Pipeline Products
Global Biosimilar Monoclonal Antibodies Market, by Indication, 2022-2030 (Value US$ Mn)
• Oncology
• Inflammatory & Autoimmune Disorders
• Chronic Diseases
• Blood Disorders
• Other Indication
Global Biosimilar Monoclonal Antibodies Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa
Why should buy this report:
To receive a comprehensive analysis of the prospects for the global Biosimilar Monoclonal Antibodies market
To receive an industry overview and future trends of the Biosimilar Monoclonal Antibodies market
To analyze the Biosimilar Monoclonal Antibodies market drivers and challenges
To get information on the Biosimilar Monoclonal Antibodies market value (US$ Mn) forecast to 2030
Significant investments, mergers & acquisitions in the Biosimilar Monoclonal Antibodies market industry
Read Overview Report- https://www.insightaceanalytic.com/report/global-biosimilar-monoclonal-antibodies-market/1218
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilar Monoclonal Antibodies Market Analysis by Product Type and Indication Forecast to 2034 here
News-ID: 4111416 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
Automotive Lead Acid Battery Market Strategic Growth Drivers and Outlook 2026 to …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Automotive Lead Acid Battery Market Size, Share & Trends Analysis Report By Product (SLI and Micro-Hybrid Batteries), Type (Flooded, Enhanced Flooded, and VRLA), Customer Segment (OEM and Aftermarket), End User (Passenger Car, Light Commercial Vehicles, Heavy Commercial Vehicles, Two-Wheeler, and Three-Wheeler), and Application (Hybrid Vehicles, Electric Vehicles, Light Motor Vehicles, and Heavy Motor Vehicles)- Market…
Automotive Interior Market Investment Opportunities and Forecast 2026 to 2035
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Automotive Interior Market- (By Component Type (Center Stack, Head-up Display, Instrument Cluster, Rear Sear Entertainment, Dome Module, Headliner, Seat, Interior Lighting Door Panel, Center Console, Adhesives & Tapes, Upholstery, Others), By Material (Leather, Fabric, Vinyl, Wood, Glass Fiber Composite, Carbon Fiber Composite, Metal), By Level of Autonomy (Semi-Autonomous, Autonomous, Non-Autonomous),By Electric Vehicle (Battery Electric Vehicle…
Artificial General Intelligence Market Future Landscape and Industry Evolution 2 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Artificial General Intelligence (AGI) Market - (By Type of Offering (Hardware, Software and Service), Type of Technology (Machine Learning, Deep Learning, Natural Language Processing and Robotics), Mode of Deployment (Cloud-based, On Premise and Web-based), Type of AI (Weak AI, Strong AI and Superintelligence), Type of Processing (Image, Text and Voice Processing), Company Size (SMEs and…
Allogenic Cell Therapies Market Revenue Trends and Growth Potential 2026 to 2035
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Allogenic Cell Therapies Market- by Cell Type(Cardiosphere-Derived Cells (CDCs), Fibroblasts, T-cells, Mesenchymal Stem Cells (MSCs), Hematopoietic Stem Cells (HSCs) and Others),Tissue Source(Skin, Blood, PBC, BM and Others), Indication (Acute graft-versus-host disease (GVHD), Chronic Ulcers and Diabetic Foot Ulcers, Osteoarthritis, Crohn's Disease, Cardiovascular Disease, Solid Tumors/Cancers and Others (Alzheimer's Disease, etc.)), Trends, Industry Competition Analysis, Revenue…
More Releases for Monoclonal
Rising Popularity Of Cost-Efficient Biosimilar Monoclonal Antibodies Fuels Monoc …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Monoclonal Antibodies (MAbs) Market Through 2025?
The market for monoclonal antibodies (MAbs) has experienced swift expansion in the recent past. The market value is projected to rise from $234.37 billion in 2024 to $261.66 billion in 2025, exhibiting a compound annual growth…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Arthritis Monoclonal Antibodies Market Report 2024 - Arthritis Monoclonal Antibo …
"The Business Research Company recently released a comprehensive report on the Global Arthritis Monoclonal Antibodies Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The arthritis monoclonal antibodies…
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02…
Monoclonal Antibody Therapy Market - Empowering the immune system: Monoclonal an …
Newark, New Castle, USA: The "Monoclonal Antibody Therapy Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Monoclonal Antibody Therapy Market: https://www.growthplusreports.com/report/monoclonal-antibody-therapy-market/7736
This latest report researches the industry structure,…
